VALN Latest Press Releases

-- January 19, 2026 --

Valneva Provides Update on Chikungunya Vaccine IXCHIQ Globe Newswire 12:00 PM

-- January 9, 2026 --

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference Globe Newswire 1:00 AM

-- December 10, 2025 --

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ Globe Newswire 11:45 AM

-- November 26, 2025 --

Valneva to Further Consolidate its Operations in France Globe Newswire 11:30 AM

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate Globe Newswire 1:00 AM

-- November 20, 2025 --

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates Globe Newswire 1:00 AM

-- November 4, 2025 --

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate Globe Newswire 1:00 AM

-- October 27, 2025 --

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences Globe Newswire 12:45 PM

-- October 18, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN PRNewswire 10:00 AM

-- October 13, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN PRNewswire 2:01 PM

-- October 8, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN PRNewswire 5:45 PM

-- October 6, 2025 --

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates Globe Newswire 11:35 AM

-- October 3, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN PRNewswire 10:00 AM

-- September 30, 2025 --

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ Globe Newswire 1:00 AM

-- September 28, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN PRNewswire 10:01 AM

-- September 24, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN Globe Newswire 4:39 PM

-- September 23, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN PRNewswire 10:00 AM

-- September 18, 2025 --

VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the Firm Globe Newswire 5:56 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN PRNewswire 10:00 AM

-- September 13, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN PRNewswire 1:45 PM

-- September 11, 2025 --

VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the Firm Globe Newswire 5:16 PM

-- September 10, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN Globe Newswire 2:21 PM

-- September 8, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN PRNewswire 3:00 PM

-- September 6, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN Globe Newswire 10:00 AM

-- September 4, 2025 --

VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the Firm Globe Newswire 5:33 PM

-- September 3, 2025 --

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate Globe Newswire 1:00 AM